While bone marrow cancer may seem like a rare diagnosis, the sobering reality is that over 35,000 Americans are expected to hear the words "multiple myeloma" this year alone, a number that brings this complex disease out of the shadows and into the light.
Key Takeaways
- Approximately 35,730 new cases of multiple myeloma (a bone marrow cancer) are expected to be diagnosed in the US in 2024.
- Multiple myeloma accounts for about 1.6% of all new cancer cases and 10% of hematologic malignancies in the US.
- The lifetime risk of developing multiple myeloma is about 0.8% (1 in 132) for American men and women.
- Family history increases multiple myeloma risk by 2-4 fold.
- African American race is associated with 2x higher risk of multiple myeloma.
- Monoclonal gammopathy of undetermined significance (MGUS) precedes 1% per year to multiple myeloma.
- About 50% of patients experience bone pain at diagnosis.
- Anemia is present in 70% of multiple myeloma patients at diagnosis.
- High levels of M protein detected in blood or urine in 97% of cases.
- Stem cell transplant is used in 50-60% of eligible patients under 70.
- Bortezomib-based regimens achieve 80% response rate.
- Lenalidomide maintenance extends PFS by 50% post-transplant.
- 5-year OS for transplant-eligible is 60%.
- Median OS for multiple myeloma is 71 months currently.
- 5-year relative survival rate is 59.8% overall.
Multiple myeloma is a relatively common bone marrow cancer with varying global risk factors.
Incidence and Prevalence
1Approximately 35,730 new cases of multiple myeloma (a bone marrow cancer) are expected to be diagnosed in the US in 2024.
Verified2Multiple myeloma accounts for about 1.6% of all new cancer cases and 10% of hematologic malignancies in the US.
Verified3The lifetime risk of developing multiple myeloma is about 0.8% (1 in 132) for American men and women.
Verified4In 2020, there were an estimated 176,404 people living with multiple myeloma in the US.
Directional5Globally, multiple myeloma incidence is around 160,000 new cases per year.
Single source6Age-adjusted incidence rate of multiple myeloma in the US is 7.1 per 100,000 people.
Verified7Multiple myeloma is more common in men than women (incidence rate 8.6 vs 6.0 per 100,000).
Verified8African Americans have nearly twice the risk of multiple myeloma compared to whites (14.2 vs 7.0 per 100,000).
Verified9Median age at diagnosis for multiple myeloma is 69 years.
Directional10Multiple myeloma represents 1.8% of all new cancer cases in the US.
Single source11In Europe, the age-standardized incidence rate for multiple myeloma is 5.5 per 100,000.
Verified12Prevalence of multiple myeloma in the US has increased by 144% from 1990 to 2020.
Verified13Annual incidence of multiple myeloma in the UK is about 5,800 cases.
Verified14Multiple myeloma incidence in Asia is lower at 1-2 per 100,000 compared to 4-7 in Western countries.
Directional15In Australia, 2,016 new cases of multiple myeloma were diagnosed in 2022.
Single source16Multiple myeloma is the 14th most common cancer worldwide.
Verified17Incidence rate of multiple myeloma increases with age, peaking at 40 per 100,000 in those over 85.
Verified18About 12,660 deaths from multiple myeloma expected in the US in 2024.
Verified19Mortality rate for multiple myeloma in the US is 2.6 per 100,000.
Directional20Multiple myeloma prevalence in Canada is about 20 per 100,000.
Single source21In India, multiple myeloma accounts for 1% of all malignancies.
Verified22US incidence of multiple myeloma rose 3.3% annually from 2014-2018.
Verified23Multiple myeloma is diagnosed in about 7 per 100,000 men annually in the US.
Verified24Global 5-year prevalence of multiple myeloma is 513,880 cases.
Directional25In Japan, multiple myeloma incidence is 3.5 per 100,000.
Single source26Multiple myeloma comprises 10-15% of hematologic cancers in the US.
Verified27Estimated 160,069 new multiple myeloma cases worldwide in 2020.
Verified28Incidence in Hispanic populations is 6.4 per 100,000 in the US.
Verified29Multiple myeloma mortality has declined 1.6% per year from 2013-2022.
Directional30About 1,718 new cases in England in 2017-2019.
Single source31Acute myeloid leukemia (AML), a bone marrow cancer, has 20,380 new US cases in 2024.
Verified32AML incidence rate 4.1 per 100,000 US population.
Verified33Chronic lymphocytic leukemia (CLL) 18,740 new cases US 2024.
Verified34Non-Hodgkin lymphoma (NHL) affecting marrow in 80,620 new cases US 2024.
DirectionalIncidence and Prevalence Interpretation
While these numbers show multiple myeloma is a relatively rare cancer by the percentage game, its staggering 144% rise in prevalence screams that it's a formidable, stealthy adversary that we can't afford to ignore.
Risk Factors and Etiology
1Family history increases multiple myeloma risk by 2-4 fold.
Verified2African American race is associated with 2x higher risk of multiple myeloma.
Verified3Monoclonal gammopathy of undetermined significance (MGUS) precedes 1% per year to multiple myeloma.
Verified4Obesity (BMI >30) increases multiple myeloma risk by 11%.
Directional5Exposure to radiation increases risk, as seen in atomic bomb survivors.
Single source6Older age (>65) is the strongest risk factor for multiple myeloma.
Verified7Male sex has 1.5x higher risk than females for multiple myeloma.
Verified8Chronic exposure to pesticides doubles multiple myeloma risk.
Verified9First-degree relatives have 3.4x increased risk.
Directional10Smoking is not strongly linked, but heavy smoking may increase risk by 10-20%.
Single source11Working in agriculture increases risk by 1.5-2x.
Verified12MGUS risk of progression to myeloma is 1% per year overall.
Verified13High-risk MGUS progresses at 5-10% per year.
Verified14Obesity linked to 20% higher risk in meta-analysis.
Directional15Exposure to benzene associated with 2-3x risk.
Single source16Genetic factors account for 15-20% of multiple myeloma heritability.
Verified17Low vitamin D levels may increase risk by 1.5x.
Verified18Firefighting occupation linked to 1.6x risk.
Verified19Sickle cell trait carriers have higher risk in African Americans.
Directional20Asbestos exposure mildly increases risk (OR 1.4).
Single source21Hyperinsulinemia associated with 2x risk.
Verified2240% of multiple myeloma patients have MGUS history.
Verified23Hair dyes (dark) use increases risk by 1.5x in women.
Verified24Chronic inflammation from autoimmune diseases raises risk.
Directional25Alcohol consumption shows inverse association (20% lower risk).
Single source26Physical activity reduces risk by 25-30%.
VerifiedRisk Factors and Etiology Interpretation
While you can't pick your ancestors, your race, or your age, you can certainly choose to put down the cigarettes, pick up a vegetable, and go for a walk, because the recipe for dodging multiple myeloma seems to be a grim cocktail of bad luck mixed with a generous pour of lifestyle choices you actually control.
Survival Rates and Prognosis
15-year OS for transplant-eligible is 60%.
Verified2Median OS for multiple myeloma is 71 months currently.
Verified35-year relative survival rate is 59.8% overall.
Verified4High-risk cytogenetics (del17p) have median OS 36 months.
Directional5Stage I (ISS) 5-year survival 82%.
Single source6Stage III (ISS) 5-year survival 40%.
Verified7Post-relapse survival improving to 40 months median.
Verified8R-ISS stage III has 3-year OS of 56%.
Verified9Triple-class refractory median OS 11.1 months.
Directional10With CAR-T, median PFS 13.3 months.
Single source11Elderly (>75) 5-year survival 47%.
Verified12African Americans have similar survival to whites after adjustments.
Verified13Median OS improved from 4.4 to 8.6 years 2000-2019.
Verified14t(4;14) translocation worsens OS to 48 months.
Directional15Gain(1q) present in 40%, reduces PFS by 20 months.
Single source16MRD negativity predicts >80% 5-year PFS.
Verified17Penta-refractory OS 5.4 months with selinexor.
Verified1810-year OS 35% for standard risk.
Verified19Renal failure at diagnosis halves median survival.
Directional20Bispecific antibodies extend OS to 15 months in RRMM.
Single source21Localized disease (rare) 5-year survival 75%.
Verified22Distant mets (most) 5-year survival 59%.
Verified23Overall survival doubled in last 20 years due to novel agents.
Verified24Median PFS first line 35 months with quadruplet therapy.
Directional25In 2023 estimates, 12,660 deaths project 5-year survival improvements.
Single source26Regional stage 5-year survival 74%.
Verified27Hypodiploidy linked to 50% reduced OS.
Verified28With maintenance, PFS >50 months post-ASCT.
Verified29Overall 10-year survival 42% in recent cohorts.
DirectionalSurvival Rates and Prognosis Interpretation
Despite the sobering odds stacked against high-risk cases, the collective climb from a median survival of 4.4 to 8.6 years proves we're not just fighting this disease but actually winning, one novel therapy and stubborn patient at a time.
Symptoms and Diagnosis
1About 50% of patients experience bone pain at diagnosis.
Verified2Anemia is present in 70% of multiple myeloma patients at diagnosis.
Verified3High levels of M protein detected in blood or urine in 97% of cases.
Verified4Bone lesions found in 80% via skeletal survey or MRI.
Directional5Hypercalcemia occurs in 25% of patients at diagnosis.
Single source6Renal insufficiency in 50% of newly diagnosed patients.
Verified7Fatigue reported by 60-70% of patients.
Verified8Serum protein electrophoresis detects monoclonal protein in 82%.
Verified9Urine protein electrophoresis positive in 75%.
Directional10Bone marrow plasmacytosis >10% in 90% of cases.
Single source11CRAB features (hyperCalcemia, Renal failure, Anemia, Bone lesions) in 75% at diagnosis.
Verified12Back pain in 58% due to fractures or lesions.
Verified13Free light chain assay abnormal in 97% of patients.
Verified14PET/CT detects lesions with 90% sensitivity.
Directional15Weight loss in 40% of advanced cases.
Single source16Infections occur in 10-15% due to immune suppression.
Verified17Neurological symptoms from cord compression in 5-10%.
Verified18Beta-2 microglobulin >3.5 mg/L indicates advanced disease in 60%.
Verified19LDH elevated in 40% correlating with poor prognosis.
Directional20Flow cytometry shows clonal plasma cells in 95% of marrow samples.
Single source21MRI shows marrow infiltration in 90% of symptomatic patients.
Verified22Biopsy confirms diagnosis in 100% with adequate sample.
Verified23Amyloidosis associated in 10-15% of cases.
Verified24Cytogenetic abnormalities detected in 40-50% via FISH.
Directional25Frequent infections like pneumonia in 20% at presentation.
Single source26Pathologic fractures in 30% within first year.
VerifiedSymptoms and Diagnosis Interpretation
The data paints a chillingly predictable blueprint of this disease: while it announces its arrival in a patient’s body through a near-perfect biochemical signature, its real cruelty lies in the brutal symphony of CRAB features—calcium poisoning the blood, kidneys faltering, bones crumbling, and blood thinning—that ravages the person long before the lab tests confirm what the body already knows.
Treatment Options and Efficacy
1Stem cell transplant is used in 50-60% of eligible patients under 70.
Verified2Bortezomib-based regimens achieve 80% response rate.
Verified3Lenalidomide maintenance extends PFS by 50% post-transplant.
Verified4Daratumumab added to VRd improves CR rate to 42% vs 32%.
Directional5CAR-T therapy (idecabtagene vicleucel) achieves 73% ORR in relapsed patients.
Single source6Bisphosphonates reduce skeletal events by 50%.
Verified7Radiation therapy used for palliation in 20-30% of patients.
Verified8Proteasome inhibitors effective in 70% of newly diagnosed.
Verified9IMiDs like pomalidomide have 30% response in refractory disease.
Directional10Selinexor + dexamethasone 26% ORR in penta-refractory patients.
Single source11Autologous SCT improves OS by 12 months median.
Verified12Teclistamab (bispecific) 63% ORR in relapsed/refractory.
Verified13Denosumab non-inferior to zoledronate, reduces renal toxicity.
Verified14Quadruplet therapy (Dara-VRd) PFS not reached vs 41 months.
Directional1590% of patients receive immunomodulators in first line.
Single source16BCMA-targeted therapies in 50% of triple-class refractory.
Verified17Erythropoietin corrects anemia in 60%.
Verified18Plasmapheresis used in 10% for hyperviscosity.
Verified19Allogeneic SCT in 5% high-risk cases, GVHD in 40%.
Directional20Elranatamab 61% ORR in heavily pretreated.
Single sourceTreatment Options and Efficacy Interpretation
The field of bone marrow cancer treatment is a chessboard where we're steadily advancing our pieces—from transplant foundations still used by over half of eligible patients to a growing arsenal of targeted strikes achieving deep responses, yet the endgame still hinges on managing the inevitable counterattacks of relapse and complications.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2GCOgco.iarc.who.intVisit source
- Reference 3SEERseer.cancer.govVisit source
- Reference 4LLSlls.orgVisit source
- Reference 5ECISecis.jrc.ec.europa.euVisit source
- Reference 6PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 7CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 8AIHWaihw.gov.auVisit source
- Reference 9GCOgco.iarc.frVisit source
- Reference 10CANCERcancer.caVisit source
- Reference 11CANCERcancer.govVisit source
- Reference 12NCBIncbi.nlm.nih.govVisit source
- Reference 13MAYOCLINICmayoclinic.orgVisit source
- Reference 14NEJMnejm.orgVisit source
- Reference 15COCHRANELIBRARYcochranelibrary.comVisit source
- Reference 16THELANCETthelancet.comVisit source